- ISIN
- US0906556065
- CUSIP
- 090655408
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jul 27, 2007
Highlights
- Market Cap
- $7.25M
- Enterprise Value
- $4.14M
- EPS (TTM)
- -$0.99
- Total Revenue (TTM)
- $357.87K
- Gross Profit (TTM)
- $224.09K
- EBITDA (TTM)
- -$12.75M
- Year Range
- $0.16 - $1.89
- ROA (TTM)
- -238.27%
- ROE (TTM)
- -365.43%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
BRTX Performance Chart
BioRestorative Therapies Inc (BRTX) is down 65.2% since the beginning of the year. At $0 per share, BRTX is trading 78.4% below its 52-week high of $2. Investors who bought $1,000 worth of BRTX shares 5 years ago would now be looking at an investment worth $14.
Loading charts...
Returns By Period
BioRestorative Therapies Inc (BRTX) has returned -65.19% so far this year and -74.11% over the past 12 months. Over the last ten years, BRTX has returned -64.99% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.
BioRestorative Therapies Inc
- 1D
- -0.15%
- 1M
- 96.63%
- YTD
- -65.19%
- 6M
- -64.74%
- 1Y
- -74.11%
- 3Y*
- -58.49%
- 5Y*
- -57.70%
- 10Y*
- -64.99%
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
BRTX Monthly Returns History
Based on dividend-adjusted daily data since May 14, 2013, BRTX's average daily return is +0.44%, while the average monthly return is +103.10%. At this rate, an investment would double in approximately 0.1 years.
Historically, 37% of months were positive and 63% were negative. The best month was Aug 2020 with a return of +17,025.0%, while the worst month was Dec 2019 at -88.1%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 9 months.
On a daily basis, BRTX closed higher 35% of trading days. The best single day was Jan 3, 2020 with a return of +404.0%, while the worst single day was Jan 6, 2020 at -59.5%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -2.98% | -79.96% | 19.13% | -17.27% | 112.35% | -14.44% | -65.19% | ||||||
| 2025 | 66.43% | -36.13% | 17.11% | -1.12% | -0.28% | -5.09% | -11.74% | 25.17% | -21.20% | 6.21% | -29.95% | 8.93% | -17.83% |
| 2024 | -6.32% | -14.11% | -1.43% | 2.90% | -11.97% | 62.40% | -24.63% | 7.19% | 6.10% | -10.34% | -1.92% | -6.54% | -17.81% |
| 2023 | 6.91% | -5.79% | 22.74% | 16.47% | 31.31% | -15.19% | -34.47% | -23.88% | -18.64% | 10.61% | -3.03% | -9.38% | -36.73% |
| 2022 | -21.89% | 64.01% | -5.94% | -19.31% | -4.50% | -26.80% | 4.40% | 6.33% | -1.37% | 0.62% | -5.54% | -10.42% | -36.64% |
| 2021 | 52.17% | 51.43% | -24.53% | -16.67% | -10.00% | -33.33% | -21.67% | -27.66% | 5.88% | -2.64% | -57.20% | -27.67% | -84.28% |
Benchmark Metrics
BioRestorative Therapies Inc has an annualized alpha of 194.39%, beta of 0.12, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since May 14, 2013.
- This stock participated in 251.75% of S&P 500 Index downside but only -67.05% of its upside - more exposed to losses than it benefited from rallies.
- Beta of 0.12 may look defensive, but with R2 of 0.00 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
- R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 194.39%
- Beta
- 0.12
- R²
- 0.00
- Upside Capture
- -67.05%
- Downside Capture
- 251.75%
Return for Risk
Risk / Return Rank
BRTX ranks 16 for risk / return — in the bottom 16% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for BioRestorative Therapies Inc (BRTX) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| BRTX | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.56 | ||
| Sortino ratioReturn per unit of downside risk | -3.18 | ||
| Omega ratioGain probability vs. loss probability | 0.94 | 1.37 | -0.43 |
| Calmar ratioReturn relative to maximum drawdown | -0.82 | 2.78 | -3.60 |
| Martin ratioReturn relative to average drawdown | -1.35 | 12.44 | -13.78 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the BioRestorative Therapies Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the BioRestorative Therapies Inc was 100.00%, occurring on May 20, 2026. The portfolio has not yet recovered.
The current BioRestorative Therapies Inc drawdown is 100.00%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2026 bear market2026 | -100.00%May 2026 | 12y 11mo | — | 13y 7dJun 2013 - now |
2013 correction2013 | -17.00%Jun 2013 | 1d | 3d | 4dJun 2013 - Jun 2013 |
2013 correction2013 | -10.00%May 2013 | 0s | 2d | 2dMay 2013 - May 2013 |
2013 pullback2013 | -1.00%May 2013 | 0s | 7d | 7dMay 2013 - May 2013 |
Drawdown Indicators
| BRTX | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -100.00% | -56.78% | -43.22% |
Max Drawdown (1Y)Largest decline over 1 year | -90.77% | -9.10% | -81.67% |
Max Drawdown (3Y)Largest decline over 3 years | -97.38% | -18.90% | -78.48% |
Max Drawdown (5Y)Largest decline over 5 years | -99.41% | -25.43% | -73.98% |
Max Drawdown (10Y)Largest decline over 10 years | -100.00% | -33.92% | -66.08% |
Current DrawdownCurrent decline from peak | -100.00% | -1.80% | -98.20% |
Average DrawdownAverage peak-to-trough decline | -88.38% | -10.71% | -77.67% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 55.06% | 2.03% | +53.03% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of BioRestorative Therapies Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how BioRestorative Therapies Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for BRTX relative to other companies in the Biotechnology industry. Currently, BRTX has a P/S ratio of 12.7. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for BRTX in comparison with other companies in the Biotechnology industry. Currently, BRTX has a P/B value of 2.4. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with BRTX
Add BioRestorative Therapies Inc to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with BRTX